Información del artículo
En la última década se ha constatado un aumento progresivo de los casos de infecciones de transmisión sexual en el territorio europeo. Las causas de este aumento no están claras, pero parece influido por cambios en las conductas sociales, los fenómenos migratorios y los viajes internacionales, junto con la aparición de grupos de riesgo no suficientemente valorados hasta ahora. La utilización habitual de técnicas de diagnóstico molecular para muchas de estas infecciones ha resuelto muchos problemas de sensibilidad e idoneidad de las muestras para el diagnóstico microbiológico, pudiéndose emplear muestras no invasivas, y ha contribuido, sin duda, a este aumento de casos. Por otro lado, los métodos moleculares también se van implantando en el estudio de la sensibilidad a los antibióticos y antivirales, así como para la caracterización molecular de los aislados. Todo lo anterior, junto a la aprobación de la vacuna frente al virus del papiloma humano, ha cambiado el panorama de las infecciones de transmisión sexual en el territorio europeo.
Palabras clave:
Infecciones de transmisión sexual
Epidemiología
Diagnóstico
Tratamiento
In the last decade, cases of sexually-transmitted infections (STIs) have progressively increased in Europe. The reasons for this increase are unclear, but may involve changes in social behavior, migration and international travel, coupled with the emergence of risk groups that have not been taken into sufficient consideration to date.
The routine use of molecular diagnostic techniques for many of these infections has solved many problems of sensitivity and the suitability of samples for microbiological diagnosis: non-invasive samples can be used, which has undoubtedly contributed to the increase in the number of cases. Moreover, molecular methods have also been introduced for antibiotic and antiviral susceptibility testing, as well as for molecular characterization of clinical isolates. All of these factors, together with the approval of the vaccine against the human papillomavirus, have changed the landscape of STIs across Europe.
Key words:
Sexually transmitted infections
Epidemiology
Diagnosis
Treatment
El Texto completo está disponible en PDF
Bibliografía
[1.]
Vigilancia epidemiológica de las ITS 1995-2006. Madrid: Instituto de Salud Carlos III; 2007 [citado Jun 2008]). Disponible en: http://www.isciii.es/htdocs/pdf/its.pdf
[2.]
M.J. Mimiaga, K.H. Mayer, S.L. Reisner, A. González, B. Dumas, R. Vanderwarker, et al.
Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men.
Sex Transm Dis, 35 (2008), pp. 495-498
[3.]
S.O. Hjelmevoll, M.E. Olsen, J.U. Sollid, H. Haaheim, K.K. Melby, H. Moi, et al.
Clinical validation of a real-time polymerase chain reaction detection of Neisseria gonorrheae porA pseudogene versus culture techniques.
Sex Transm Dis, 35 (2008), pp. 517-520
[4.]
J. Moncada, E. Donegan, J. Schachter.
Evaluation of CDC-recommended approaches for confirmatory testing of positive Neisseria gonorrhoeae nucleic acid amplification test results.
J Clin Microbiol, 46 (2008), pp. 1614-1619
[5.]
K.J. Craib, D.R. Meddings, S.A. Strathdee, R.S. Hogg, J.S. Montaner, M.V. O'Shaughnessy, et al.
Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men.
Genitourin Med, 71 (1995), pp. 150-154
[6.]
K.A. Mangold, M. Regner, M. Tajuddin, A.M. Tajuddin, L. Jennings, H. Du, et al.
Neisseria species identification assay for the confirmation of Neisseria gonorrhoeae-positive results of the COBAS Amplicor PCR.
J Clin Microbiol, 45 (2007), pp. 1403-1409
[7.]
L. Otero, M. Álvarez-Arguelles, H. Villar, J. Díaz-Gigante, F. Carreño, F. Vázquez.
The prevalence of Neisseria gonorrhoeae negative for proline iminopeptidase in Asturias, Spain.
Sex Transm Infect, 83 (2007), pp. 76
[8.]
F. Vernel-Pauillac, F. Merien.
A novel real-time duplex PCR assay for detecting penA and ponA genotypes in Neisseria gonorrhoeae: comparison with phenotypes determined by the E-test.
Clin Chem, 52 (2006), pp. 2294-2296
[9.]
M.J. Siedner, M. Pandori, L. Castro, P. Barry, W.L. Whittington, S. Liska, et al.
Real-time PCR assay for detection of quinolone-resistant Neisseria gonorrhoeae in urine samples.
J Clin Microbiol, 45 (2007), pp. 1250-1254
[10.]
S. Ochiai, H. Ishiko, M. Yasuda, T. Deguchi.
Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA gene, which is associated with decreased susceptibilities to oral cephalosporins.
J Clin Microbiol, 46 (2008), pp. 1804-1810
[11.]
Anónimo WHO.
Trends in sexually transmitted infections and HIV in the European Region, 1980-2005. Technical briefing document 01B/06.
World Health Organization, (2006),
[12.]
S. Kapoor.
Re-emergence of lymphogranuloma venereum.
J Eur Acad Dermatol Venereol, 22 (2008), pp. 409-416
[13.]
C. Carder, D. Mercey, P. Benn.
Chlamydia trachomatis.
Sex Transm Infect, 82 (2006), pp. iv10-iv12
[14.]
L. Marions, M. Rotzen-Ostlund, L. Grillner, K. Edgardh, A. Tiveljung-Lindell, A. Wikstrom, et al.
High occurrence of a new variant of Chlamydia trachomatis escaping diagnostic tests among STI clinic patients in Stockholm, Sweden.
Sex Transm Dis, 35 (2008), pp. 61-64
[15.]
A. Herring, J. Richens.
Lymphogranuloma venereum.
Sex Transm Infect, 82 (2006), pp. iv23-iv25
[16.]
C.Y. Chen, K.H. Chi, S. Alexander, C. Ison, R.C. Ballard.
A real-time quadriplex PCR assay for the diagnosis of rectal lymphogranuloma venereum (LGV) and non-LGV Chlamydia trachomatis infections.
Sex Transm Infect, (2008),
[17.]
Anónimo. Centers for Disease Control and Prevention.
Sexually transmitted diseases treatment guidelines.
MMWR, 55 (2006), pp. 1-93
[18.]
T. Yoshida, T. Deguchi, S. Meda, Y. Kubota, M. Tamaki, S. Yokoi, et al.
Quantitative detection of Ureaplasma parvum (biovar 1) and Ureaplasma urealyticum (biovar 2) in urine specimens from men with and without urethritis by real-time polymerase chain reaction.
Sex Transm Dis, 34 (2007), pp. 416-419
[19.]
J.K. Wroblewski, L.E. Manhart, K.A. Dickey, M.K. Hudspeth, P.A. Totten.
Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium.
J Clin Microbiol, 44 (2006), pp. 3306-3312
[20.]
L. Falk, H. Fredlund, J.S. Jensen.
Tetracycline treatment does not eradicate Mycoplasma genitalium.
Sex Transm Infect, 79 (2003), pp. 318-319
[21.]
T. Deguchi, S. Maeda, M. Tamaki, T. Yoshida, H. Ishiko, M. Ito, et al.
Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment.
J Antimicrob Chemother, 48 (2001), pp. 742-744
[22.]
A. Nicoll, F.F. Hamers.
Are trends in HIV, gonorrhoea, and syphilis worsening in western Europe?.
BMJ, 324 (2002), pp. 1324-1327
[23.]
O. Lupi, V. Madkan, S.K. Tyring.
Tropical dermatology: bacterial tropical diseases.
J Am Acad Dermatol, 54 (2006), pp. 559-578
[24.]
I.M. Mackay, G. Harnett, N. Jeoffreys, I. Bastian, K.S. Sriprakash, D. Siebert, et al.
Detection and discrimination of herpes simplex viruses, Haemophilus ducreyi, Treponema pallidum, and Calymmatobacterium (Klebsiella) granulomatis from genital ulcers.
Clin Infect Dis, 42 (2006), pp. 1431-1438
[25.]
M. Alfa.
The laboratory diagnosis of Haemophilus ducreyi.
Can J Infect Dis Med Microbiol, 16 (2005), pp. 31-34
[26.]
P.A. Totten, J.M. Kuypers, C.Y. Chen, M.J. Alfa, L.M. Parsons, S.M. Dutro, et al.
Etiology of genital ulcer disease in Dakar, Senegal, and comparison of PCR and serologic assays for detection of Haemophilus ducreyi infection.
J Clin Microbiol, 38 (2000), pp. 268-273
[27.]
K. Patterson, B. Olsen, C. Thomas, D. Norn, M. Tam, C. Elkins.
Development of a rapid immunodiagnostic test for Haemophilus ducreyi.
J Clin Microbiol, 40 (2002), pp. 3694-3702
[28.]
J.S. Smith, N.J. Robinson.
Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review.
J Infect Dis, 186 (2002), pp. S3-S28
[30.]
M. Ramaswamy, C. McDonald, M. Smith, D. Thomas, S. Maxwell, M. Tenant-Flowers, et al.
Diagnosis of genital herpes by real-time PCR in routine clinical practice.
Sex Transm Infect, 80 (2004), pp. 406-410
[31.]
A. Wald.
Testing for genital herpes: how, who, and why.
Curr Clin Top Infect Dis, 22 (2002), pp. 166-180
[32.]
B. Romanowski, R.B. Marina, J.N. Roberts.
Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study.
Sex Transmit Dis, 30 (2003), pp. 226-231
[33.]
R. Stranska, R. Schuurman, E. Nienhuis, I. Goedegebuure, M. Polman, J. Weel, et al.
Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization.
J Clin Virol, 32 (2005), pp. 7-18
[34.]
R. Gupta, E.L. Hill, D. McClernon, G. Davis, S. Selke, L. Corey, et al.
Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women.
J Infect Dis, 192 (2005), pp. 1102-1107
[35.]
S. Safrin, T. Elbeik, L. Phan, D. Robinson, J. Rush, A. Elbaggari, et al.
Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus infected patients.
Antimicrob Agents Chemother, 38 (1994), pp. 1246-1250
[36.]
A.A. Chentoufi, X. Zhang, K. Lamberth, G. Dasgupta, I. Bettahi, A. Nguyen, et al.
HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D.
J Immunol, 180 (2008), pp. 426-437
[37.]
L.R. Stanberry.
Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
Herpes, 11 (2004), pp. 161-169A
[38.]
J. Marrone, C.K. Fairley, M. Saville, C. Bradshaw, F.J. Bowden, L.B. Horvath, et al.
Temporal associations with declining Trichomonas vaginalis diagnosis rates among women in the State of Victoria, Australia, 1947 to 2005.
Sex Transm Dis, 35 (2008), pp. 572-576
[39.]
A.M. Caliendo, J.A. Jordan, A.M. Green, J. Ingersoll, R.J. Diclemente, G.M. Wingood.
Real-time PCR improves detection of Trichomonas vaginalis infection compared with culture using self-collected vaginal swabs.
Infect Dis Obstet Gynecol, 13 (2005), pp. 145-150
[40.]
P. Simpson, G. Higgins, M. Qiao, R. Waddell, T. Kok.
Real-time PCRs for detection of Trichomonas vaginalis beta-tubulin and 18S rRNA genes in female genital specimens.
J Med Microbiol, 56 (2007), pp. 772-777
[41.]
J. Ingersoll, T. Bythwood, D. Abdul-Ali, G.M. Wingood, R.J. Diclemente, A.M. Caliendo.
Stability of Trichomonas vaginalis DNA in urine specimens.
J Clin Microbiol, 46 (2008), pp. 1628-1630
[42.]
P. Kissinger, W.E. Secor, J.S. Leichliter, R.A. Clark, N. Schmidt, E. Curtin, et al.
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Clin Infect Dis, 46 (2008), pp. 994-999
[43.]
S. Pérez, A. Fernández-Verdugo, F. Pérez, F. Vázquez.
Prevalence of 5-nitroimidazole-resistant Trichomonas vaginalis in Oviedo, Spain.
Sex Transm Dis, 28 (2001), pp. 115-116
[44.]
L.A. Koutsky, D.A. Galloway, K.K. Holmes.
Epidemiology of genital human papillomavirus infection.
Epidemiol Rev, 10 (1988), pp. 122-163
[45.]
Health Protection Agency. Trends in genital warts and genital herpes diagnoses in the United Kingdom. Health Protection Report. 2007;35:4-5 [citado, Jun 2008]). Disponible en: http://www.hpa.org.uk/hpr/archives/2007/hpr3507.pdf
[46.]
M. Frisch, C. Fenger, van den Brule, P. Sørensen, C.J. Meijer, J.M. Walboomers, et al.
Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus.
Cancer Res, 59 (1999), pp. 753-757
[47.]
C.M. Nielson, R. Flores, R.B. Harris, M. Abrahamsen, M.R. Papenfuss, E.F. Dunne, et al.
Human papillomavirus prevalence and type distribution in male anogenital sites and semen.
Cancer Epidemiol Biomarkers Prev, 16 (2007), pp. 1107-1114
[48.]
G. Sanclemente, S. Herrera, S.K. Tyring, P.L. Rady, J.J. Zuleta, L.A. Correa, et al.
Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.
J Eur Acad Dermatol Venereol, 21 (2007), pp. 1054-1060
[49.]
S.K. Tyring, I. Arany, M.A. Stanley, M. Tomai, R. Miller, M. Smith, et al.
A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.
J Infect Dis, 178 (1998), pp. 551-555
[50.]
E. Stockfleth, H. Beti, R. Orasan, F. Grigorian, A. Mescheder, H. Tawfik, et al.
Topical polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.
Br J Dermatol, 158 (2008), pp. 1329-1338
[51.]
S. Gupta, A. Malhotra, K. Verma, V. Sharma.
Intralesional immunotherapy with killed Mycobacterium w vaccine for the treatment of ano-genital warts: an open label pilot study.
J Eur Acad Dermatol Venereol, (2008),
[52.]
K.A. Ault.
Human papillomavirus vaccines and the potential for cross-protection between related HPV types.
Gynecol Oncol, 107 (2007), pp. S31-S33
[53.]
L. Otero, J.A. Varela, E. Espinosa, C. Sánchez, M.L. Junquera, A. del Valle, et al.
Sarcoptes scabiei in a sexually transmitted infections unit: a 15-year study.
Sex Transm Dis, 31 (2004), pp. 761-765
[54.]
S.F. Walton, B.J. Currie.
Problems in diagnosing scabies, a global disease in human and animal populations.
Clin Microbiol Rev, 20 (2007), pp. 268-279
[55.]
M. Strong, P.W. Johnstone.
Interventions for treating scabies.
Cochrane Database Syst Rev, 3 (2007),
[56.]
J.A. Varela, L. Otero, E. Espinosa, C. Sánchez, M.L. Junquera, F. Vázquez.
Phthirus pubis in a sexually transmitted diseases unit: a study of 14 years.
Sex Transm Dis, 30 (2003), pp. 292-296
[57.]
R. Speare, J.M. Koehler.
A case of pubic lice resistant to pyrethrins.
Aust Fam Physician, 30 (2001), pp. 572-574
[58.]
P.A. Leone.
Scabies and pediculosis pubis: an update of treatment regimens and general review.
Clin Infect Dis, 44 (2007), pp. S153-S159
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
